BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33334316)

  • 1. Brimonidine-associated uveitis - a descriptive case series.
    Hopf S; Mercieca K; Pfeiffer N; Prokosch-Willing V
    BMC Ophthalmol; 2020 Dec; 20(1):489. PubMed ID: 33334316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brimonidine Induced Anterior Uveitis.
    Beltz J; Zamir E
    Ocul Immunol Inflamm; 2016; 24(2):128-33. PubMed ID: 26399160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine.
    Clemente-Tomás R; Arciniegas-Perasso CA; Hervás-Hernandis JM; García-Ibor F; Ruiz-Del Río N; Duch-Samper AM
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Oct; 93(10):511-514. PubMed ID: 29910082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution.
    Casado A; Cabarga C; de la Fuente MA; Muñoz-Negrete FJ
    Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2659-60. PubMed ID: 23835755
    [No Abstract]   [Full Text] [Related]  

  • 5. Anterior uveitis as a side effect of topical brimonidine.
    Byles DB; Frith P; Salmon JF
    Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre.
    Kóthy P; Holló G
    Int Ophthalmol; 2020 Feb; 40(2):377-383. PubMed ID: 31650353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
    Kim KE; Lee CK; Shin J; Kim Y; Rho S
    Sci Rep; 2023 Apr; 13(1):5700. PubMed ID: 37029145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST; Samuelson TW
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservative-free
    Duru Z; Ozsaygili C
    Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
    [No Abstract]   [Full Text] [Related]  

  • 14. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
    Watts P; Hawksworth N
    Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
    Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
    Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
    J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.